Evidence map›Paper›PMID 31133018›Full record

ArticleWorld journal of surgical oncology2019

Analysis of patients scheduled for neoadjuvant therapy followed by surgery for esophageal cancer, who never made it to esophagectomy.

Lieven Depypere, Melissa Thomas, Johnny Moons, Willy Coosemans, Toni Lerut, Hans Prenen, Karin Haustermans, Hans Van Veer, Philippe Nafteux

Abstract read
In one paragraph

Article in World journal of surgical oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. The Oesophageal Cancer Multidisciplinary Team: Can Machine Learning Assist Decision-Making?Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2023
    Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Lieven DepypereDepartment of Thoracic Surgery, University Hospitals Leuven, Herestraat 49, 3000, Leuven, Belgium. lieven.depypere@uzleuven.be.
Melissa ThomasDepartment of Radiation Oncology, University Hospitals Leuven, Leuven, Belgium.
Johnny MoonsDepartment of Thoracic Surgery, University Hospitals Leuven, Herestraat 49, 3000, Leuven, Belgium.
Willy CoosemansDepartment of Thoracic Surgery, University Hospitals Leuven, Herestraat 49, 3000, Leuven, Belgium.
Toni LerutDepartment of Thoracic Surgery, University Hospitals Leuven, Herestraat 49, 3000, Leuven, Belgium.
Hans PrenenDepartment of Oncology, University Hospital Antwerp, Edegem, Belgium.
Karin HaustermansDepartment of Radiation Oncology, University Hospitals Leuven, Leuven, Belgium.
Hans Van VeerDepartment of Thoracic Surgery, University Hospitals Leuven, Herestraat 49, 3000, Leuven, Belgium.
Philippe NafteuxDepartment of Thoracic Surgery, University Hospitals Leuven, Herestraat 49, 3000, Leuven, Belgium.

Funding

Clinical research fund, university hospitals Leuven naFonds Wetenschappelijk Onderzoek naKom op tegen Kanker naStichting Tegen Kanker na
6 · The paper itself

Abstract

backgroundNeoadjuvant treatment followed by esophagectomy is standard practice in locally advanced esophageal cancer. However, not all patients who started neoadjuvant treatment will undergo esophageal resection. The purpose of our study was to investigate the group of patients, scheduled for neoadjuvant treatment followed by esophagectomy, who never made it to esophageal resection.

methodsWe retrospectively analyzed patients treated between 2002 and 2015 for locally advanced esophageal cancer, who did not undergo esophagectomy after neoadjuvant treatment. Subanalysis was performed according to time period (2002-2010 versus 2011-2015) and histology (adenocarcinoma versus squamous cell carcinoma).

resultsIn 114 of 679 patients (16.8%), surgery was not performed after neoadjuvant treatment. Reasons for cancelation were disease progression (50 patients, 43.9%), poor general condition (26 patients, 22.8%), irresectability (14 patients, 12.3%), patients' own decision (15 patients, 13.2%), and death during neoadjuvant treatment (9 patients, 7.9%). In the second time period, there were less irresectable tumors (17.7% versus 5.8%; p = 0.044). Median overall survival was not different over time (9.2 versus 12.5 months; p = 0.937). Irresectability (p = 0.032), patients' refusal (p = 0.012), and poor general condition (p = 0.002) were more frequent as reasons for cancelation in squamous cell carcinoma patients. Median overall survival was, respectively, 12.5 and 9.9 months for adenocarcinoma and squamous cell carcinoma patients (p = 0.441). The majority of patients refusing surgery had a clinical complete response (73.3%). They had a median overall survival of 33.2 months.

conclusionsOne in six patients starting neoadjuvant treatment for locally advanced esophageal cancer never made it to esophagectomy, more than half of them for oncological reasons, but also 1.3% because of death during treatment. Over time, irresectability as reason decreased. As a result, the relative weight of medical inoperability increased, indicating the importance of upfront testing of medical operability. Cancelation of surgery was significantly more common in patients with a squamous cell carcinoma, and this histology seems to represent a more complex oncological and functional entity. Refusal of esophagectomy based on clinical complete response showed a significant survival benefit compared to those who did not undergo esophagectomy because of other reasons.

Indexed as

AdenocarcinomaAdultAgedAged, 80 and overCarcinoma, Squamous CellChemoradiotherapy, AdjuvantCombined Modality TherapyEsophageal NeoplasmsEsophagectomyFemaleFollow-Up StudiesHumansMaleMiddle AgedNeoadjuvant TherapyNeoplasm Recurrence, LocalAdverse effectsEsophageal neoplasmsNeoadjuvant therapyTreatment outcome

Identifiers

PMID31133018
PMCPMC6537364

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.